Our lead program, telitacicept, is a potential best- and first-in-class dual BAFF/APRIL inhibitor designed to silence the signals that drive maturation, proliferation and survival that fuel harmful B cells including harmful self reactive B cells, cutting off the cascade of autoantibody production and downstream damage.
To deliver therapies that restore balance to the immune system and meaningfully improve patients’ lives.
To become the global leader in targeted therapeutics for autoimmune disease.
We are committed to advancing transformative therapies that move beyond symptom control to deliver durable, disease-modifying benefits. By challenging conventional approaches and focusing on the upstream drivers of autoimmunity, Vor is building a new generation of medicines with the potential to dramatically improve patients’ lives across multiple autoimmune conditions.
Vor is led by a proven team of biopharma innovators with deep expertise in autoimmune disease, biologics development, and commercialization. Together, our team brings the drive to accelerate telitacicept’s path forward and transform the lives of patients with autoimmune disease.
Our Board brings together diverse experience and deep expertise to guide Vor’s mission of transforming autoimmune care. By combining our talents, challenging one another to think bigger, and partnering with leading scientists and innovators worldwide, we are accelerating the path to novel therapies that tackle disease at its root.
Chief Executive Officer and Chairman
Dr. Kress brings decades of executive leadership experience in the pharmaceutical and biotech industries. He most recently served as Chief Executive Officer of MorphoSys, where he led the development, approval and commercialization of Monjuvi® (tafasitamab), and advanced the company’s pipeline through the landmark ...
Chief Financial Officer, Chief Business Officer
Mr. Mahatme joins Vor Bio with more than 30 years of executive leadership experience in the biopharmaceutical industry, with a strong track record in capital markets, business development, global operations, and shareholder value creation. He most recently served as President, Chief Operating Officer, and Chief ...
Chief Medical Officer
Dr. Sokolove brings more than 18 years of experience leading clinical development and translational research in autoimmune and inflammatory diseases across biotechnology and pharmaceutical organizations.
Prior to joining Vor Bio, Dr. Sokolove was Chief Medical Officer In-Residence at Roivant Sciences, where he led ...
Chief Commercial Officer
Mr. Murray brings more than 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies.
He joins Vor Bio from Sarepta Therapeutics, where he most recently served as Executive Vice President, Chief Customer Officer. In ...
General Counsel
Dr. Osovsky brings nearly two decades of legal experience across biotechnology, public company governance, securities law, capital markets, business development, and complex transactions. She joins Vor Bio from iTeos Therapeutics, where she served as Executive Vice President, Head of Legal and Corporate Secretary. In ...
Chief Medical Affairs Officer
Dr. Navid Khan brings more than 20 years of experience across Medical Affairs, R&D, and Commercial functions, with deep expertise in neurology, immunology, and rare diseases.
Prior to joining Vor Bio, Dr. Khan served as Head of the Neuromuscular Therapeutic Area ...
Head of Human Resources
Carol Lincoln brings more than 25 years of experience leading human resources strategy, total rewards, and operations across the biotechnology, pharmaceutical, financial services, and publishing industries.
She joins Vor Bio from iTeos Therapeutics, where she most recently served as Head of Total Rewards ...
Dr. Kress brings decades of executive leadership experience in the pharmaceutical and biotech industries. He most recently served as Chief Executive Officer of MorphoSys, where he led the development, approval and commercialization of Monjuvi® (tafasitamab), and advanced the company’s pipeline through the landmark acquisition of Constellation Pharmaceuticals in 2021, strengthening MorphoSys’ position in oncology innovation and ultimately leading to its subsequent acquisition by Novartis in 2024. Prior to that, he was CEO of Syntimmune, guiding its lead immunology program through to acquisition by Alexion Pharmaceuticals. He currently serves on the Board of Sanofi S.A. and has held senior roles across leading biopharma companies. Dr. Kress holds graduate and post-graduate degrees in biochemistry and molecular and cellular pharmacology from Ecole normale superieure, Paris, and an MD from Faculte Necker-Enfants Malades, Paris.
Mr. Mahatme joins Vor Bio with more than 30 years of executive leadership experience in the biopharmaceutical industry, with a strong track record in capital markets, business development, global operations, and shareholder value creation. He most recently served as President, Chief Operating Officer, and Chief Financial Officer of National Resilience, Inc., a biomanufacturing company he co-founded in 2020. During his tenure, he raised over $2.5 billion in equity and non-dilutive capital.
Prior to Resilience, Mr. Mahatme served as Executive Vice President, Chief Financial Officer and Chief Business Officer of Sarepta Therapeutics, where he led capital formation efforts exceeding $3.5 billion and built the company’s pipeline through a series of strategic licenses, collaborations, and acquisitions. He also served as Senior Vice President, Corporate Development and Corporate Treasurer and Senior Vice President, Tax at Celgene Corporation. Mr. Mahatme currently serves on the boards of CRISPR Therapeutics and Idorsia Pharmaceuticals. He holds Master of Laws degrees from Cornell Law School and New York University School of Law and is a member of the New York Bar.
Dr. Sokolove brings more than 18 years of experience leading clinical development and translational research in autoimmune and inflammatory diseases across biotechnology and pharmaceutical organizations.
Prior to joining Vor Bio, Dr. Sokolove was Chief Medical Officer In-Residence at Roivant Sciences, where he led strategic assessment and in-licensing of novel therapeutic programs and provided clinical and operational leadership across Roivant’s portfolio companies. Previously, he served as Chief Medical Officer at Odyssey Therapeutics, guiding the company’s transition to a clinical-stage organization developing next-generation immunomodulators for autoimmune and inflammatory diseases.Earlier in his career, Dr. Sokolove held senior leadership positions at GlaxoSmithKline as Senior Vice President and Head of Clinical Pharmacology & Experimental Medicine, and at AbbVie as Head of Immunology Translational Science.
An accomplished physician-scientist and rheumatologist, Dr. Sokolove was previously on the faculty at Stanford University Medical Center. He earned his MD from Boston University School of Medicine and completed his Internal Medicine residency at Boston University Medical Center, where he served as Chief Medical Resident. He completed clinical and research fellowships in Rheumatology and Immunology at Stanford University.
Mr. Murray brings more than 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies.
He joins Vor Bio from Sarepta Therapeutics, where he most recently served as Executive Vice President, Chief Customer Officer. In that role, he led the commercial and medical affairs organizations, along with the international business unit. Under his leadership, Sarepta achieved approximately $1.8 billion in net product revenue in 2024. While at Sarepta he oversaw multiple product launches, including the launch of the first RNA therapy and first gene therapy for duchenne muscular dystrophy.
Over the course of his career, Mr. Murray has led or supported more than a dozen product launches, including INCIVEK at Vertex Pharmaceutics, Inc., the fastest launch to $1 billion in biotech history at the time, and multiple global rollouts at Gilead Sciences, Inc., Biogen Inc., and Johnson & Johnson.
Mr. Murray holds an MBA from Queen’s University in Ontario, Canada, and a Bachelor of Commerce from the University of Alberta.
Dr. Osovsky brings nearly two decades of legal experience across biotechnology, public company governance, securities law, capital markets, business development, and complex transactions. She joins Vor Bio from iTeos Therapeutics, where she served as Executive Vice President, Head of Legal and Corporate Secretary. In that role, she led the company’s legal, corporate governance and compliance functions, advised the Board, CEO and executive team on strategic matters, and oversaw information technology.
Previously, Dr. Osovsky held senior legal roles at Sarepta Therapeutics, where she advised on corporate transactions, securities matters, governance, global expansion, strategic collaborations and capital markets transactions during a period of significant growth and transformation.
Earlier in her career, Dr. Osovsky practiced at Sullivan & Worcester LLP and Gornitzky & Co., advising public companies, underwriters, buyers, sellers and major corporate clients on securities offerings, M&A, corporate governance, regulatory matters and complex litigation.
Dr. Osovsky holds an LLB from Tel Aviv University and both an LLM and SJD in Securities Regulation from Harvard Law School.
Dr. Navid Khan brings more than 20 years of experience across Medical Affairs, R&D, and Commercial functions, with deep expertise in neurology, immunology, and rare diseases.
Prior to joining Vor Bio, Dr. Khan served as Head of the Neuromuscular Therapeutic Area in Medical Affairs at argenx, leading four major product launches of efgartigimod (VYVGART & VYVGART HYTRULO) for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), and overseeing a fully integrated neuromuscular medical affairs team. Earlier in his career, Dr. Khan held senior medical affairs and commercial leadership positions at Akouos as VP of Medical Affairs, and at Sarepta Therapeutics as Executive Director of Global Medical Affairs, and Head of HCP Marketing.
Dr. Khan earned his PhD in Biomedical Engineering and Biotechnology from the University of Massachusetts Lowell and his BS in Biochemistry and Molecular Biology from the University of Massachusetts Amherst.
Carol Lincoln brings more than 25 years of experience leading human resources strategy, total rewards, and operations across the biotechnology, pharmaceutical, financial services, and publishing industries.
She joins Vor Bio from iTeos Therapeutics, where she most recently served as Head of Total Rewards and U.S. Human Resources. In that role, she led the creation and build-out of the company’s U.S. HR function.Prior to iTeos, Carol served as Director of Total Rewards at Finch Therapeutics and Director of Total Rewards and Operations at Cyclerion Therapeutics, where she helped establish Human Resources infrastructure following its spin-out from Ironwood Pharmaceuticals. Earlier in her career, she was with Ironwood Pharmaceuticals, where she held a series of Human Resources leadership roles.
Carol holds a BA in English from the University of Massachusetts Amherst and is a Certified Compensation Professional (CCP).
